Literature DB >> 16803608

Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas.

V Cottet1, A Pariente, B Nalet, J Lafon, C Milan, S Olschwang, J Faivre, C Bonaiti-Pellié, C Bonithon-Kopp.   

Abstract

BACKGROUND: Little is known about compliance with colonoscopy as a screening method in first-degree relatives of patients with large adenomas. Aims To evaluate the compliance with screening colonoscopy among this population, and its determinants.
METHODS: Data were obtained from the family part of the GEADE study, a study on genetic factors of colorectal adenomas. Index cases were 306 patients with adenomas > or = 10 mm. All living first-degree relatives aged 40-75 who could be contacted by the index case were asked to undergo a colonoscopy, unless they had had one in the previous 5 years.
RESULTS: Among 674 eligible relatives, 56 had had a colonoscopy within the preceding 5 years and 114 underwent a screening colonoscopy resulting in a compliance with screening colonoscopy of 18%. This was not related to most characteristics of index cases. Compliance was significantly lower when the index case lived in the Greater Paris area than when he/she lived in other areas (12% vs. 21%). It was higher in siblings (18%) and offspring (23%) than in parents (9%) and in relatives under 55 years old (22%) than in relatives aged 55 and over (15%).
CONCLUSIONS: Compliance with colonoscopy was low in first-degree relatives of patients with large adenomas. The reasons for this should be determined and appropriate strategies developed to increase compliance.

Entities:  

Mesh:

Year:  2006        PMID: 16803608     DOI: 10.1111/j.1365-2036.2006.02966.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Do individuals with a family history of colorectal cancer adhere to medical recommendations for the prevention of colorectal cancer?

Authors:  Karen Bronner; Ilse Mesters; Ahuva Weiss-Meilnik; Ravit Geva; Guy Rozner; Hana Strul; Moshe Inbar; Zamir Halpern; Revital Kariv
Journal:  Fam Cancer       Date:  2013-12       Impact factor: 2.375

2.  Analysis of candidate genes in occurrence and growth of colorectal adenomas.

Authors:  Sylviane Olschwang; Déwi Vernerey; Vanessa Cottet; Alexandre Pariente; Bernard Nalet; Jacques Lafon; Jean Faivre; Pierre Laurent-Puig; Claire Bonithon-Kopp; Catherine Bonaiti-Pellié
Journal:  J Oncol       Date:  2009-10-29       Impact factor: 4.375

3.  Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma.

Authors:  Astrid Lièvre; Jacqueline Milet; Jérôme Carayol; Delphine Le Corre; Chantal Milan; Alexandre Pariente; Bernard Nalet; Jacques Lafon; Jean Faivre; Claire Bonithon-Kopp; Sylviane Olschwang; Catherine Bonaiti-Pellié; Pierre Laurent-Puig
Journal:  BMC Cancer       Date:  2006-11-24       Impact factor: 4.430

Review 4.  Increased Risk of Colorectal Cancer Tied to Advanced Colorectal Polyps: An Untapped Opportunity to Screen First-Degree Relatives and Decrease Cancer Burden.

Authors:  Jennifer M Kolb; Christine L Molmenti; Swati G Patel; David A Lieberman; Dennis J Ahnen
Journal:  Am J Gastroenterol       Date:  2020-07       Impact factor: 12.045

5.  Examining the challenges of family recruitment to behavioral intervention trials: factors associated with participation and enrollment in a multi-state colonoscopy intervention trial.

Authors:  Rebecca G Simmons; Yuan-Chin Amy Lee; Antoinette M Stroup; Sandra L Edwards; Amy Rogers; Christopher Johnson; Charles L Wiggins; Deirdre A Hill; Rosemary D Cress; Jan Lowery; Scott T Walters; Kory Jasperson; John C Higginbotham; Marc S Williams; Randall W Burt; Marc D Schwartz; Anita Y Kinney
Journal:  Trials       Date:  2013-04-30       Impact factor: 2.279

6.  Quality indicators to assess a colorectal cancer prevention program.

Authors:  Victoria Serra-Sutton; Carmela Barrantes Serrano; Mireia Espallargues Carreras
Journal:  Int J Technol Assess Health Care       Date:  2013-04-15       Impact factor: 2.188

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.